SEC EDGARJUN 41 min read$DRTS

Levy Raphi sold $352K of DRTS

Levy Raphi (Chief Financial Officer) sold 32,500 shares of Alpha Tau Medical Ltd. (DRTS) at an average of $10.83 ($10.76–$10.90, $0.35M total) across 2 trades on 2026-06-03.

Original reporting

SEC EDGAR · Levy Raphi

Published Jun 4, 2026, 6:29 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 28, 2026, 3:50 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$DRTS

Bearish

medium confidence

Mentioned

$DRTS

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$DRTSBearishLow

Why it matters

The CFO's sale may be interpreted by investors as a bearish cue, though the amount is modest.

Market read

A routine insider sale with limited material impact.

What to watch

No accompanying earnings or guidance change; the transaction size is small relative to market cap.

Relevance 4/10Novelty 3/10Timing: post-market today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$DRTSBearishMedium confidence

Context

CFO Levy Raphi sold 32,500 shares of Alpha Tau Medical Ltd. for $352,115.25 on 2026-06-03.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size but involves the CFO; such transactions often lead to short-term downside.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

Limited to markets where Alpha Tau Medical trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

Company
Alpha Tau Medical Ltd.
Issuer of the shares sold.
Individual
Levy Raphi
Chief Financial Officer and reporting insider.

Read at source ← All news

SEP 15

$DRTSHighAI 9/10

Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.

Alpha Tau Medical (NASDAQ: DRTS) reported strong results from cancer trials, including a 100% response rate in head and neck cancer and promising data in brain and pancreatic cancers. The company expects key data readouts in late 2026 and early 2027, which could impact its trajectory. Alpha Tau has $104.8 million in cash and a U.S. commercialization partnership with Tolmar.

investegate.co.uk3 min

JUL 21

$DRTSMedAI 8/10

Alpha Tau Shows 100% ORR With Alpha DaRT Plus Keytruda In Head And Neck Squamous Cell Carcinoma

Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.

rttnews.com4 min

JUL 15

$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min

JUN 23

$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min

JUN 4

$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.